New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for ...

Despite low obesity rates, Korea sees high demand for Wegovy, prompting misuse and regulatory concerns amid societal pressures regarding beauty standards and weight.

comes as third-party companies are being restricted from selling compounded versions of Wegovy (semaglutide), as the drug is no longer on the FDA shortage list. A huge market for compounded ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

The high monthly costs of GLP-1s — ranging from $1,000 to $1,500 — are placing considerable financial pressure on healthcare ...